Compounds > acetylglycyrrhetinic acid
Page last updated: 2024-12-07

acetylglycyrrhetinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acetylglycyrrhetinic acid (AG) is a derivative of glycyrrhizic acid, the main active component of licorice root. It exhibits a wide range of pharmacological activities, including anti-inflammatory, antiviral, and immunomodulatory effects. AG has been studied extensively for its potential therapeutic applications in various diseases, such as inflammatory bowel disease, hepatitis, and cancer. Its anti-inflammatory properties are attributed to its ability to inhibit the production of pro-inflammatory cytokines. AG also possesses antiviral activity against a variety of viruses, including HIV and influenza. Its immunomodulatory effects involve the regulation of immune cell activation and cytokine production. The synthesis of AG typically involves acetylation of glycyrrhizic acid, a process that enhances its bioavailability and stability. The importance of AG research lies in its potential to develop new drugs for the treatment of a wide range of diseases. Studies continue to explore its mechanisms of action and therapeutic potential.'

acetylglycyrrhetinic acid: RN given refers to (3beta,20beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID94320
CHEMBL ID207413
CHEBI ID81306
SCHEMBL ID135617
MeSH IDM0061122

Synonyms (42)

Synonym
nsc35349
6277-14-1
nsc-35349
10-acetyloxy-2,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid
acetylglycyrrhetic acid
glycyrrhetic acid acetate
acetylglycyrrhetinic acid
einecs 228-475-1
(3beta,20beta)-3-acetoxy-11-oxoolean-12-en-29-oic acid
glycyrrhetinic acid acetate
olean-12-en-29-oic acid, 3-(acetyloxy)-11-oxo-, (3-beta,20-beta)-
3-acetyl-18-beta-glycyrrhetinic acid
(3-beta,20-beta)-3-(acetyloxy)-11-oxo-olean-12-en-29-oic acid
acetoxolone
glycyrrhetinyl acetate
nsc 35349
bdbm50188385
(3beta,18beta,20beta)-3-(acetyloxy)-11-oxo-olean-12-en-29-oic acid
(2s,4as,6as,6br,8ar,10s,12as,12br,14br)-10-acetoxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
C17734
chebi:81306 ,
dgs 0110a
dgs-0110a
uralenic acid, acetate
CHEMBL207413 ,
(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-acetyloxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid
unii-cww961q19k
cww961q19k ,
olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-, acetate
AKOS016036176
(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-acetoxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid
olean-12-en-30-oic acid, 3-.beta.-hydroxy-11-oxo-, acetate
SCHEMBL135617
3-o-acetyl-18.beta.-glycyrrhetic acid
acetoxolone [mi]
(3.beta.,20.beta.)-3-(acetyloxy)-11-oxoolean-12-en-29-oic acid
3.beta.-hydroxy-11-oxoolean-12-en-30-oic acid acetate
olean-12-en-29-oic acid, 3-(acetyloxy)-11-oxo-, (3.beta.,20.beta.)-
acetoxolone [who-dd]
DB13640
Q4673282
DTXSID801031583

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Human carboxylesterase 2 (hCE2), one of the major carboxylesterases in the human intestine and various tumour tissues, plays important roles in the oral bioavailability and treatment outcomes of ester- or amide-containing drugs or prodrugs, such as anticancer agents CPT-11 (irinotecan) and LY2334737 (gemcitabine)."( Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
Ge, GB; Hao, DC; Hou, J; Jin, Q; Li, YG; Wang, P; Yang, L; Zhou, K; Zou, LW, 2016)		0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)IC50 (µMol)18.80000.00751.36125.5000AID265993
Corticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)IC50 (µMol)4.62200.00411.066710.0000AID265989; AID265997; AID526983; AID587113
17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)IC50 (µMol)3.78000.09603.94009.9000AID265995
Corticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)IC50 (µMol)2.03270.00040.63676.4300AID265990; AID265998; AID526982; AID587116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
steroid biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estrogen biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
lysosome organization17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
skeletal muscle tissue development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estrogen metabolic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
gene expression17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
bone development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
adipose tissue development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cellular response to metal ion17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
lung developmentCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
steroid catabolic processCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
in utero embryonic development17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
placenta development17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
estrogen biosynthetic process17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
androgen metabolic process17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
response to retinoic acid17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
steroid metabolic process17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
response to hypoxiaCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
regulation of blood volume by renal aldosteroneCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
female pregnancyCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
response to xenobiotic stimulusCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
response to foodCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
response to insulinCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
cortisol metabolic processCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
response to glucocorticoidCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
glucocorticoid metabolic processCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
catalytic activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
steroid binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
small molecule binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein homodimerization activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
NADP binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
NADP+ binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estradiol binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein homodimerization activityCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
7-beta-hydroxysteroid dehydrogenase (NADP+) activityCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
NADP bindingCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
11-beta-hydroxysteroid dehydrogenase (NADP+) activityCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
cortisol dehydrogenase activityCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
steroid bindingCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
steroid bindingCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
NAD bindingCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
11-beta-hydroxysteroid dehydrogenase (NAD+) activityCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytoplasm17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cytosol17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cytosol17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
endoplasmic reticulum membraneCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
membraneCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
endoplasmic reticulum membraneCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
intracellular membrane-bounded organelleCorticosteroid 11-beta-dehydrogenase isozyme 1Homo sapiens (human)
endoplasmic reticulum membrane17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
intracellular membrane-bounded organelle17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
endoplasmic reticulum membraneCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
intracellular membrane-bounded organelleCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
intracellular membrane-bounded organelleCorticosteroid 11-beta-dehydrogenase isozyme 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID745025Antifilarial activity against female adult Brugia malayi assessed as inhibition of MTT reduction at LC100 concentration after 24 hrs2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Glycyrrhetinic acid and its analogs: a new class of antifilarial agents.
AID265993Inhibition of human recombinant 17betaHSD1 expressed in HEK293 cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID456097Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as oxidation of [1,2,6,7-3H]cortisol to cortisone at 1 uM after 10 mins by scintillation counting2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Synthesis of glycyrrhetinic acid derivatives for the treatment of metabolic diseases.
AID456095Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-3H]cortisone to cortisol at 1 uM after 10 mins by scintillation counting2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Synthesis of glycyrrhetinic acid derivatives for the treatment of metabolic diseases.
AID659366Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID659367Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV by hepatitis B e-antigen release detection assay2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID587111Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as residual conversion of [1,2-[3H]cortisone to cortisol at 1000 nM after 10 mins by scintillation counting2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID659363Cytotoxicity against human HepG2(2.2.15) cells2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID587114Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as residual conversion of [1,2,6,7-[3H]cortisol to cortisone at 1000 nM after 10 mins by scintillation counting2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID265991Inhibition of human recombinant 11-beta-HSD1 expressed in HEK293 cells at 10 uM2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID265995Inhibition of human recombinant 17-beta-HSD2 expressed in HEK293 cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID1285099Inhibition of CE2 in human liver microsomes using fluorescein diacetate as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by LC-UV analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
AID1285100Inhibition of CE1 in human liver microsomes using 2-(2-Benzoyl-3-methoxyphenyl) benzothiazole as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by LC-UV analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
AID526984Selectivity ratio of IC50 for human recombinant 11beta-HSD2 to IC50 for human recombinant 11beta-HSD12010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID265990Inhibition of human recombinant 11-beta-HSD2 expressed in HEK293 cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID265997Inhibition of human recombinant 11-beta-HSD1 transfected in intact HEK293 cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID659369Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV by viral DNA replication detection assay2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID659365Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV by hepatitis B surface antigen release detection assay2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID526982Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-3H]-cortisol to cortisone by scintillation counting2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID659364Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID587113Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-[3H]cortisone to cortisol after 10 mins by scintillation counting2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID1285101Selectivity ratio of IC50 for CE1 in human liver microsomes to IC50 for CE2 in human liver microsomes2016European journal of medicinal chemistry, Apr-13, Volume: 112Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2.
AID587117Selectivity ratio of IC50 for human 11beta-HSD1 to IC50 for human 11beta-HSD22011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID343737Inhibition of chymotrypsin-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
AID265998Inhibition of human recombinant 11betaHSD2 transfected in intact HEK293 cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID265989Inhibition of human recombinant 11-beta-HSD1 expressed in HEK293 cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID526979Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as residual conversion of [1,2-3H]-cortisone to cortisol at 1 uM by scintillation counting2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID745023Antifilarial activity against microfilariae Brugia malayi assessed as inhibition of motility after 24 hrs by microscopic analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Glycyrrhetinic acid and its analogs: a new class of antifilarial agents.
AID526978Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as residual conversion of [1,2,6,7-3H]-cortisol to cortisone at 1 uM by scintillation counting2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID265988Cytotoxicity against HEK293 cells upto 40 uM by MTT assay2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID526983Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [1,2-3H]-cortisone to cortisol by scintillation counting2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID659368Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID587116Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [1,2,6,7-[3H]cortisol to cortisone after 10 mins by scintillation counting2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
AID745024Antifilarial activity against female adult Brugia malayi assessed as inhibition of motility after 24 hrs by microscopic analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Glycyrrhetinic acid and its analogs: a new class of antifilarial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.92 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bis(4-nitrophenyl)phosphate
bis(4-nitrophenyl)phosphate: RN given refers to parent cpd		2.1310aryl phosphate
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		1.9610benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
aldosterone
[no description available]		2.031011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
glycyrrhetinic acid
[no description available]		3.4570cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		2.0510enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
diethylcarbamazine citrate
[no description available]		2.0810piperazinecarboxamide
3-oxoglycyrrhetinic acid
[no description available]		3.1750pentacyclic triterpenoid
calpain inhibitor 2
calpain inhibitor 2: inhibits degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and some other cysteine proteinases		2.0410peptide
cortisone
[no description available]		2.031011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		2.0710nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
carbenoxolone sodium
Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.		1.9610triterpenoid
carbenoxolone
[no description available]		2.9740
lactacystin
[no description available]		2.0410lactam;
S-substituted L-cysteine
bavachinin
bavachinin: do not confuse with bavachin		2.1310flavanones
11-deoxy glycyrrhetinic acid
[no description available]		2.520triterpenoid
ConditionIndicatedRelationship StrengthStudiesTrials
Diseases, Metabolic
[description not available]		02.0510
Metabolic Diseases
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)		02.0510
Gastroduodenal Ulcer
[description not available]		01.9610
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		13.9610